These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33861693)

  • 41. What Might Aducanumab Teach Us About Clinicians' Judgment About Whether to Recommend Emerging Alzheimer's Interventions?
    Burroughs AW; Krain LP
    AMA J Ethics; 2023 Oct; 25(10):E777-782. PubMed ID: 37801063
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Navigating Disease-Modifying Treatments for Alzheimer's Disease: Focusing on Medications in Phase 3 Clinical Trials.
    Brandt NJ; Wheeler C; Courtin SO
    J Gerontol Nurs; 2023 Jan; 49(1):6-10. PubMed ID: 36594914
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The FDA Approves Aducanumab for Alzheimer's Disease, Raising Important Scientific Questions1.
    de la Torre JC; Gonzalez-Lima F
    J Alzheimers Dis; 2021; 82(3):881-882. PubMed ID: 34250943
    [No Abstract]   [Full Text] [Related]  

  • 44. Regulatory decisions diverge over aducanumab for Alzheimer's disease.
    Lythgoe MP; Jenei K; Prasad V
    BMJ; 2022 Jan; 376():e069780. PubMed ID: 35091420
    [No Abstract]   [Full Text] [Related]  

  • 45. A contentious FDA ruling for Alzheimer's disease.
    The Lancet Neurology
    Lancet Neurol; 2021 Aug; 20(8):585. PubMed ID: 34237273
    [No Abstract]   [Full Text] [Related]  

  • 46. Unwanted Advice? Frequency, Characteristics, And Outcomes Of Negative Advisory Committee Votes For FDA-Approved Drugs.
    Daval CJR; Sarpatwari A; Kesselheim AS
    Health Aff (Millwood); 2022 May; 41(5):713-721. PubMed ID: 35500185
    [TBL] [Abstract][Full Text] [Related]  

  • 47. US FDA defends approval of Alzheimer's disease drug.
    Jaffe S
    Lancet; 2021 Jul; 398(10294):12. PubMed ID: 34217382
    [No Abstract]   [Full Text] [Related]  

  • 48. Aducanumab Fails to Produce Efficacy Results Yet Obtains US Food and Drug Administration Approval.
    Angelo M; Ward L
    Popul Health Manag; 2021 Dec; 24(6):638-639. PubMed ID: 34516238
    [No Abstract]   [Full Text] [Related]  

  • 49. FDA's dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps.
    Rizk JG; Lewin JC
    BMJ Evid Based Med; 2023 Apr; 28(2):78-82. PubMed ID: 35450946
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Questions EMERGE as Biogen claims aducanumab turnaround.
    Howard R; Liu KY
    Nat Rev Neurol; 2020 Feb; 16(2):63-64. PubMed ID: 31784690
    [No Abstract]   [Full Text] [Related]  

  • 51. The Problem of Aducanumab for the Treatment of Alzheimer Disease.
    Alexander GC; Karlawish J
    Ann Intern Med; 2021 Sep; 174(9):1303-1304. PubMed ID: 34138642
    [No Abstract]   [Full Text] [Related]  

  • 52. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
    Piazza F; Winblad B
    J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FDA approves Alzheimer's drug lecanemab amid safety concerns.
    Reardon S
    Nature; 2023 Jan; 613(7943):227-228. PubMed ID: 36627422
    [No Abstract]   [Full Text] [Related]  

  • 54. Aducanumab and the Business of Alzheimer Disease-Some Choice.
    Karlawish J
    JAMA Neurol; 2021 Nov; 78(11):1303-1304. PubMed ID: 34410302
    [No Abstract]   [Full Text] [Related]  

  • 55. Donanemab: FDA experts recommend approval of Alzheimer's drug.
    Dyer O
    BMJ; 2024 Jun; 385():q1327. PubMed ID: 38876494
    [No Abstract]   [Full Text] [Related]  

  • 56. Diarrhea drug rejection raises a ruckus.
    Cadman J
    GMHC Treat Issues; 1998 May; 12(5):1-3. PubMed ID: 11365474
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Of education and public policy: Aducanumab.
    Lundebjerg NE; Hollmann PA; Supiano MA
    J Am Geriatr Soc; 2022 Jan; 70(1):81-84. PubMed ID: 34674219
    [No Abstract]   [Full Text] [Related]  

  • 58. Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease.
    Zissimopoulos J; Jacobson M; Chen Y; Borson S
    JAMA Netw Open; 2022 Feb; 5(2):e2148355. PubMed ID: 35157058
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aducanumab for Alzheimer's disease?
    Walsh S; Merrick R; Milne R; Brayne C
    BMJ; 2021 Jul; 374():n1682. PubMed ID: 34226181
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.
    Budd Haeberlein S; O'Gorman J; Chiao P; Bussière T; von Rosenstiel P; Tian Y; Zhu Y; von Hehn C; Gheuens S; Skordos L; Chen T; Sandrock A
    J Prev Alzheimers Dis; 2017; 4(4):255-263. PubMed ID: 29181491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.